Kinnate Biopharma
Stock Forecast, Prediction & Price Target
Kinnate Biopharma Financial Estimates
Kinnate Biopharma Revenue Estimates
Kinnate Biopharma EBITDA Estimates
Kinnate Biopharma Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $61.33M Low: $61.33M High: $61.33M avg. 0% | Avg: $197.05M Low: $197.05M High: $197.05M avg. 221.28% |
Net Income
% change YoY
| $-89.41M N/A | $-114.02M -27.51% | $-112.64M 1.20% | Avg: $-52.75M Low: $-44.24M High: $-33.06M avg. 53.16% | Avg: $-68.90M Low: $-45.17M High: $-31.20M avg. -30.60% | Avg: $-51.69M Low: $-51.69M High: $-51.69M avg. 24.97% | Avg: $-17.69M Low: $-17.69M High: $-17.69M avg. 65.76% |
EBITDA
% change YoY
| $-89.98M N/A | $-117.91M -31.03% | $-118.20M -0.24% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$2.05 N/A | -$2.59 -26.34% | -$2.42 6.56% | Avg: -$0.86 Low: -$0.95 High: -$0.71 avg. 64.46% | Avg: -$0.82 Low: -$0.97 High: -$0.67 avg. 4.65% | Avg: -$1.11 Low: -$1.11 High: -$1.11 avg. -35.36% | Avg: -$0.38 Low: -$0.38 High: -$0.38 avg. 65.76% |
Operating Expenses
% change YoY
| $90.11M N/A | $118.52M 31.52% | $118.20M -0.26% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Kinnate Biopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 28.32% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -44.24M, average is -52.75M and high is -33.06M.
What is Kinnate Biopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 55.32% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Kinnate Biopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 24.87% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$0.95, average is -$0.86 and high is $-0.71.
What is the best performing analyst?
In the last twelve months analysts have been covering Kinnate Biopharma stock. The most successful analyst is Christopher Raymond.